Jianxin Pang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jianxin Pang has a total of 292 co-authors. Here are the top co-authors by number of shared publications:
Ting Wu
Southern Medical University 1838 North Guangzhou Ave
27 shared publicationsFengxin Zheng
NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening & Guangdong-Hongkong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China
15 shared publicationsYing Cao
NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong Provincial Key Laboratory of New Drug Screening & Guangdong-Hongkong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, 1838 Guangzhou Avenue North, Guangzhou, 510515, China
15 shared publicationsZean Zhao
NMPA Key Laboratory for Research and Evaluation of Drug Metabolism & Guangdong‐Hongkong‐Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical Sciences Southern Medical University Guangzhou China
15 shared publicationsHui Liao
NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, Guangdong-Hongkong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China
13 shared publicationsLu Li
NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, Guangdong-Hongkong-Macao Joint Laboratory for New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China
11 shared publications
Latest Publications
- 14 August 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (17) , 20911-20942
Rational Design of Azaindole Derivatives via a Nitrogen-Walk Strategy from β-Carboline: Discovery of Highly Selective, Low-Toxicity URAT1 Inhibitors as Potent Urate-Lowering Agents
Hyperuricemia-induced gout is largely driven by impaired renal urate excretion, while current URAT1 inhibitors suffer from OAT1-mediated off-target toxicity. Our lead compound E1 potently inhibited URAT1 (IC50 = 3.02 μM) and reduced serum uric acid but exhibited OAT1 inhibition (IC50 = 4.78 μM) and HK-2 cytotoxicity (CC50 = 46.22 μM). To improve selectivity while retaining the core pharmacophore, a nitrogen-walk strategy was applied to design 48 azaindole derivatives. Pyrrolo[3,2-d]pyrimidine-based compound 17 was identified as the optimized candidate, exhibiting URAT1 inhibition (IC50 = 5.32 μM) with reduced OAT1 inhibition (IC50 = 30.11 μM), achieving a 6.7-fold selectivity improvement over E1. Compound 17 reduced serum uric acid by 77.7% at 2 mg/kg in an acute hyperuricemia mouse model and alleviated hepatic and renal injury in a chronic hyperuricemia model. It exhibited favorable druggability, including 87.9% oral bioavailability, a minimum effective dose below 0.5 mg/kg, and no observable toxicity up to 1000 mg/kg.
- 14 August 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (17) , 20911-20942
Rational Design of Azaindole Derivatives via a Nitrogen-Walk Strategy from β-Carboline: Discovery of Highly Selective, Low-Toxicity URAT1 Inhibitors as Potent Urate-Lowering Agents
Hyperuricemia-induced gout is largely driven by impaired renal urate excretion, while current URAT1 inhibitors suffer from OAT1-mediated off-target toxicity. Our lead compound E1 potently inhibited URAT1 (IC50 = 3.02 μM) and reduced serum uric acid but exhibited OAT1 inhibition (IC50 = 4.78 μM) and HK-2 cytotoxicity (CC50 = 46.22 μM). To improve selectivity while retaining the core pharmacophore, a nitrogen-walk strategy was applied to design 48 azaindole derivatives. Pyrrolo[3,2-d]pyrimidine-based compound 17 was identified as the optimized candidate, exhibiting URAT1 inhibition (IC50 = 5.32 μM) with reduced OAT1 inhibition (IC50 = 30.11 μM), achieving a 6.7-fold selectivity improvement over E1. Compound 17 reduced serum uric acid by 77.7% at 2 mg/kg in an acute hyperuricemia mouse model and alleviated hepatic and renal injury in a chronic hyperuricemia model. It exhibited favorable druggability, including 87.9% oral bioavailability, a minimum effective dose below 0.5 mg/kg, and no observable toxicity up to 1000 mg/kg.
- Open Access
- 3 August 2026
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 40 (8) , e71058
Isobavachin Attenuates Renal and Cardiac Injury in Chronic Hyperuricemia via Modulation of NF‐κB and NLRP3 Signaling Pathways
Hyperuricaemia (HUA) is a recognized risk factor for cardiovascular and renal diseases. Isobavachin, a dihydroflavone derivative, demonstrates significant efficacy in reducing uric acid levels. This study investigated the nephroprotective and cardioprotective effects and molecular mechanisms of isobavachin. Through integrative network pharmacology, pathway enrichment analysis, and molecular docking, NF‐κB was identified as a potential target of isobavachin in the context of hyperuricemia‐related cardiac and renal injury. Isobavachin treatment inhibited the activation of the NF‐κB pathway, leading to cytoprotection in uric acid (UA)‐stimulated mRTEC and H9C2 cells. In chronic HUA mice, isobavachin treatment significantly improved renal pathology and reduced renal collagen deposition by inhibiting epithelial‐to‐mesenchymal transition. Isobavachin administration demonstrated therapeutic efficacy in attenuating myocardial injury, hypertrophy, and fibrotic remodeling. Notably, the anti‐inflammatory effects of isobavachin were particularly evident in both renal and cardiac tissues, primarily mediated through its dual regulatory capacity in suppressing NF‐κB pathway activation and NLRP3 inflammasome formation. In conclusion, isobavachin ameliorated cardiac and renal damage caused by chronic HUA, suggesting a new strategy to prevent HUA.
- 3 August 2026
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 40 (8) , e71058
Open AccessIsobavachin Attenuates Renal and Cardiac Injury in Chronic Hyperuricemia via Modulation of NF‐κB and NLRP3 Signaling Pathways
Hyperuricaemia (HUA) is a recognized risk factor for cardiovascular and renal diseases. Isobavachin, a dihydroflavone derivative, demonstrates significant efficacy in reducing uric acid levels. This study investigated the nephroprotective and cardioprotective effects and molecular mechanisms of isobavachin. Through integrative network pharmacology, pathway enrichment analysis, and molecular docking, NF‐κB was identified as a potential target of isobavachin in the context of hyperuricemia‐related cardiac and renal injury. Isobavachin treatment inhibited the activation of the NF‐κB pathway, leading to cytoprotection in uric acid (UA)‐stimulated mRTEC and H9C2 cells. In chronic HUA mice, isobavachin treatment significantly improved renal pathology and reduced renal collagen deposition by inhibiting epithelial‐to‐mesenchymal transition. Isobavachin administration demonstrated therapeutic efficacy in attenuating myocardial injury, hypertrophy, and fibrotic remodeling. Notably, the anti‐inflammatory effects of isobavachin were particularly evident in both renal and cardiac tissues, primarily mediated through its dual regulatory capacity in suppressing NF‐κB pathway activation and NLRP3 inflammasome formation. In conclusion, isobavachin ameliorated cardiac and renal damage caused by chronic HUA, suggesting a new strategy to prevent HUA.
- 26 May 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (11) , 13099-13120
Pyridoimidazolyl Sulfonamide Compound 2 : A Superior Dual-Acting Drug Candidate with Potent URAT1 Inhibition and Anti-Inflammatory Activity for Gout Management
The management of hyperuricemia and gout remains constrained by the narrow therapeutic index of current drugs. To improve the druggability of our previously identified URAT1 inhibitor T7, we replaced its carboxylic acid with a sulfonamide group. A total of 40 novel derivatives were synthesized, among which 23 derivatives exhibited robust in vivo serum uric acid-lowering activity. Lead compound 2 (bearing a p-bromobenzenesulfonamide) exhibited potent URAT1 inhibition (IC50 = 0.19 μM) and significantly lowered serum uric acid in hyperuricemic mice (96.8% reduction) and rats (91.9% reduction). Notably, compound 2 also inhibited IL-1β activity (IC50 = 3.39 μM), which may enhance its therapeutic potential in gout by targeting disease-associated inflammation. Compound 2 demonstrated favorable pharmacokinetics (half-life: 6.3 h, oral bioavailability: 20.1%) and high safety (MTD > 1000 mg/kg). These results establish compound 2 as a promising dual-acting candidate for gout therapy.
- 26 May 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (11) , 13099-13120
Pyridoimidazolyl Sulfonamide Compound 2 : A Superior Dual-Acting Drug Candidate with Potent URAT1 Inhibition and Anti-Inflammatory Activity for Gout Management
The management of hyperuricemia and gout remains constrained by the narrow therapeutic index of current drugs. To improve the druggability of our previously identified URAT1 inhibitor T7, we replaced its carboxylic acid with a sulfonamide group. A total of 40 novel derivatives were synthesized, among which 23 derivatives exhibited robust in vivo serum uric acid-lowering activity. Lead compound 2 (bearing a p-bromobenzenesulfonamide) exhibited potent URAT1 inhibition (IC50 = 0.19 μM) and significantly lowered serum uric acid in hyperuricemic mice (96.8% reduction) and rats (91.9% reduction). Notably, compound 2 also inhibited IL-1β activity (IC50 = 3.39 μM), which may enhance its therapeutic potential in gout by targeting disease-associated inflammation. Compound 2 demonstrated favorable pharmacokinetics (half-life: 6.3 h, oral bioavailability: 20.1%) and high safety (MTD > 1000 mg/kg). These results establish compound 2 as a promising dual-acting candidate for gout therapy.
- 6 May 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (10) , 11752-11775
Discovery of a Novel Thienopyrimidine Derivative as a Potent Dual URAT1/GLUT9 Inhibitor with Enhanced Urate-Lowering Efficacy, Superior Pharmacokinetics, and Favorable Safety Profile for Gout and Hyperuricemia
Gout and hyperuricemia, caused by high serum uric acid, require safer and more effective treatments due to the toxicity and limited efficacy of current drugs. Dual inhibition of URAT1 and GLUT9 may reduce renal toxicity compared to single-target approaches. Starting from lead compound F-5, we used scaffold hopping and structure-guided design to develop 46 novel polycyclic pyrimidine derivatives. Among these, compound 17 showed potent and balanced inhibition of URAT1 (IC50 = 4.01 μM) and GLUT9 (IC50 = 1.60 μM), greatly improving upon F-5. Additionally, 17 reduced serum uric acid levels by 82.4% in hyperuricemic mice, while it exhibited favorable pharmacokinetic profiles in rats (F = 33.71 vs 20.13% for F-5). Significantly, 17 was efficacious at a low dose (0.5 mg/kg) and showed no acute toxicity at 1000 mg/kg. These results support 17 as a promising dual URAT1/GLUT9 inhibitor with improved efficacy, pharmacokinetics, and safety for treating gout and hyperuricemia.
- 6 May 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (10) , 11752-11775
Discovery of a Novel Thienopyrimidine Derivative as a Potent Dual URAT1/GLUT9 Inhibitor with Enhanced Urate-Lowering Efficacy, Superior Pharmacokinetics, and Favorable Safety Profile for Gout and Hyperuricemia
Gout and hyperuricemia, caused by high serum uric acid, require safer and more effective treatments due to the toxicity and limited efficacy of current drugs. Dual inhibition of URAT1 and GLUT9 may reduce renal toxicity compared to single-target approaches. Starting from lead compound F-5, we used scaffold hopping and structure-guided design to develop 46 novel polycyclic pyrimidine derivatives. Among these, compound 17 showed potent and balanced inhibition of URAT1 (IC50 = 4.01 μM) and GLUT9 (IC50 = 1.60 μM), greatly improving upon F-5. Additionally, 17 reduced serum uric acid levels by 82.4% in hyperuricemic mice, while it exhibited favorable pharmacokinetic profiles in rats (F = 33.71 vs 20.13% for F-5). Significantly, 17 was efficacious at a low dose (0.5 mg/kg) and showed no acute toxicity at 1000 mg/kg. These results support 17 as a promising dual URAT1/GLUT9 inhibitor with improved efficacy, pharmacokinetics, and safety for treating gout and hyperuricemia.
- 17 April 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (9) , 10764-10787
A Novel Pyrrole Acylsulfonamide, Compound 42 , as a Dual URAT1/GLUT9 Inhibitor: Potent Urate-Lowering Efficacy, Reduced Off-Target Effects, and Promising Druggability for Hyperuricemia
Hyperuricemia and gout remain challenging due to the limited efficacy and safety of current therapies. Herein, we report a novel pyrrole acylsulfonamide, compound 42, rationally designed via structural simplification of lead compounds E1 and ZS-24, targeting urate transporters. In acute hyperuricemia mice, compound 42 demonstrated potent urate-lowering efficacy with a decrease ratio of 88.76%, significantly superior to Lesinurad (39.02%). Mechanistically, it synergistically inhibited URAT1 (IC50 = 2.81 ± 0.40 μM) and GLUT9 (IC50 = 12.53 ± 1.33 μM), with reduced off-target activity on OAT1 (IC50 = 7.83 ± 0.70 μM vs ZS-24’s 4.90 ± 0.99 μM) to mitigate potential toxicity. It displayed superior ligand efficiency (LE = 0.44 vs ZS-24’s 0.41) and favorable pharmacokinetics (T1/2 = 5.55 h, F = 51.3%). In hyperuricemic nephropathy mice, compound 42 reduced serum uric acid and protected renal function without acute and subacute toxicity at high doses, supporting its promise as a candidate for hyperuricemia and gout.
- 17 April 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (9) , 10764-10787
A Novel Pyrrole Acylsulfonamide, Compound 42 , as a Dual URAT1/GLUT9 Inhibitor: Potent Urate-Lowering Efficacy, Reduced Off-Target Effects, and Promising Druggability for Hyperuricemia
Hyperuricemia and gout remain challenging due to the limited efficacy and safety of current therapies. Herein, we report a novel pyrrole acylsulfonamide, compound 42, rationally designed via structural simplification of lead compounds E1 and ZS-24, targeting urate transporters. In acute hyperuricemia mice, compound 42 demonstrated potent urate-lowering efficacy with a decrease ratio of 88.76%, significantly superior to Lesinurad (39.02%). Mechanistically, it synergistically inhibited URAT1 (IC50 = 2.81 ± 0.40 μM) and GLUT9 (IC50 = 12.53 ± 1.33 μM), with reduced off-target activity on OAT1 (IC50 = 7.83 ± 0.70 μM vs ZS-24’s 4.90 ± 0.99 μM) to mitigate potential toxicity. It displayed superior ligand efficiency (LE = 0.44 vs ZS-24’s 0.41) and favorable pharmacokinetics (T1/2 = 5.55 h, F = 51.3%). In hyperuricemic nephropathy mice, compound 42 reduced serum uric acid and protected renal function without acute and subacute toxicity at high doses, supporting its promise as a candidate for hyperuricemia and gout.
- 13 February 2026
- Published by Elsevier in Biochemical Pharmacology
- Vol. 247, 117810
An allosteric SHP2 inhibitor suppresses breast cancer-induced osteoclastogenesis and bone lysis
- 13 February 2026
- Published by Elsevier in Biochemical Pharmacology
- Vol. 247, 117810
An allosteric SHP2 inhibitor suppresses breast cancer-induced osteoclastogenesis and bone lysis
- 8 January 2026
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 40 (1) , e70682
Isobavachin Ameliorates Acetaminophen‐Induced Liver Injury Through Modulation of CYP2E1‐Mediated Bioactivation and NRF2/PI3K/AKT Cytoprotective Pathways
Acetaminophen (APAP)‐induced liver injury (AILI) remains a critical clinical challenge with limited therapeutic options. This research elucidates the mechanisms through which the natural flavonoid isobavachin (ISO) confers protection against APAP‐induced liver injury. In vivo experiments demonstrated that ISO treatment significantly attenuated histopathological parameters, oxidative stress and inflammation, as indicated by serum ALT/AST, MDA, SOD/GSH, TNF‐α/IL‐1β levels. Mechanistically, ISO inhibited CYP2E1 expression and promoted NRF2 activation. Furthermore, integrated network pharmacology, transcriptomics, and molecular docking simulations revealed the PI3K/AKT signaling pathway as a potential targets of ISO, demonstrating high‐affinity confirmed between ISO and PI3K (‐8.6 kcal/mol) or AKT (‐6.4 kcal/mol) respectively. western blotting assay confirmed that ISO activated PI3K/AKT signaling and upregulated downstream anti‐apoptotic‐ protein BCL2. These findings collectively suggest that ISO alleviates AILI through multi‐mechanisms: inhibiting CYP2E1‐mediated APAP bioactivation, modulating of the NRF2/PI3K/AKT signaling, ISO attenuates oxidative damage, suppresses inflammatory activation, and inhibits apoptosis. The results suggest that ISO represents a potential therapeutic agent for managing APAP‐induced hepatotoxicity.
- 8 January 2026
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 40 (1) , e70682
Isobavachin Ameliorates Acetaminophen‐Induced Liver Injury Through Modulation of CYP2E1‐Mediated Bioactivation and NRF2/PI3K/AKT Cytoprotective Pathways
Acetaminophen (APAP)‐induced liver injury (AILI) remains a critical clinical challenge with limited therapeutic options. This research elucidates the mechanisms through which the natural flavonoid isobavachin (ISO) confers protection against APAP‐induced liver injury. In vivo experiments demonstrated that ISO treatment significantly attenuated histopathological parameters, oxidative stress and inflammation, as indicated by serum ALT/AST, MDA, SOD/GSH, TNF‐α/IL‐1β levels. Mechanistically, ISO inhibited CYP2E1 expression and promoted NRF2 activation. Furthermore, integrated network pharmacology, transcriptomics, and molecular docking simulations revealed the PI3K/AKT signaling pathway as a potential targets of ISO, demonstrating high‐affinity confirmed between ISO and PI3K (‐8.6 kcal/mol) or AKT (‐6.4 kcal/mol) respectively. western blotting assay confirmed that ISO activated PI3K/AKT signaling and upregulated downstream anti‐apoptotic‐ protein BCL2. These findings collectively suggest that ISO alleviates AILI through multi‐mechanisms: inhibiting CYP2E1‐mediated APAP bioactivation, modulating of the NRF2/PI3K/AKT signaling, ISO attenuates oxidative damage, suppresses inflammatory activation, and inhibits apoptosis. The results suggest that ISO represents a potential therapeutic agent for managing APAP‐induced hepatotoxicity.
- 19 December 2025
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 296, 118323
Integrated aptamer-based DNAzyme motor with pattern recognition for discriminative intracellular uric acid biosensing and high-throughput GLUT9 inhibitor discovery
- 19 December 2025
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 296, 118323
Integrated aptamer-based DNAzyme motor with pattern recognition for discriminative intracellular uric acid biosensing and high-throughput GLUT9 inhibitor discovery
- Open Access
- 20 November 2025
- Published by Elsevier in Pharmacological Research
- Vol. 222, 108039
PXR activation ameliorates hyperuricemic nephropathy via NRF2 signaling
- 20 November 2025
- Published by Elsevier in Pharmacological Research
- Vol. 222, 108039
Open AccessPXR activation ameliorates hyperuricemic nephropathy via NRF2 signaling
- Open Access
- 4 October 2025
- Published by Elsevier in Phytomedicine
- Vol. 148, 157368
Isobavachin alleviates hyperuricemia-induced bone loss by GPR35-NLRP3 signal
- 4 October 2025
- Published by Elsevier in Phytomedicine
- Vol. 148, 157368
Open AccessIsobavachin alleviates hyperuricemia-induced bone loss by GPR35-NLRP3 signal